| Filed On | Filing |
|---|---|
| 06 Nov 2026 | SCHEDULE 13G/A |
| 05 Nov 2026 | SCHEDULE 13G |
| 04 Nov 2026 | 144 |
| 03 Nov 2026 | 10-Q |
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition
SAN DIEGO – November 3, 2026 – Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases w... |
| 28 Oct 2026 | SCHEDULE 13G |
| 28 Oct 2026 | SCHEDULE 13G/A |
| 22 Oct 2026 | SCHEDULE 13G |
| 01 Oct 2026 | 144 |
| 14 Sep 2026 |
8-K: Other Events
–Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpoint |
| 08 Sep 2026 |
Form 4: Stengone Carmine N., Director
Received 2,500 shares by exercise or conversion ($2.53K) · Sold 2,500 shares ($41.1K) |
| 08 Sep 2026 | 144 |
| 01 Sep 2026 | 144 |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 03 Aug 2026 |
Form 4: Stengone Carmine N., Director
Received 2,500 shares by exercise or conversion ($2.53K) · Sold 2,500 shares ($40K) |
| 03 Aug 2026 | 144 |
| 03 Aug 2026 | 144 |
| 30 Jul 2026 | 10-Q |
| 30 Jul 2026 |
8-K: Results of Operations and Financial Condition
SAN DIEGO – July 30, 2026 – Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with... |
| 27 Jul 2026 | SCHEDULE 13G |
Loading...